These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36240845)

  • 1. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
    Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
    J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
    Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
    Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
    Strobel SB; Machiraju D; Kälber KA; Hassel JC
    Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
    JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
    Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
    Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
    Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
    JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Guo M; Liu J; Miao R; Ahmed Z; Yu J; Guan J; Ahmad S; Zhou S; Grove A; Manoucheri M; Socinski MA; Mekhail T
    J Immunother; 2022 Nov-Dec 01; 45(9):389-395. PubMed ID: 36066505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
    Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Chong CR; Park VJ; Cohen B; Postow MA; Wolchok JD; Kamboj M
    Clin Infect Dis; 2020 Jan; 70(2):193-199. PubMed ID: 30874791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors.
    Sumimoto H; Noda S; Koide H; Douke Y; Sakai K; Nishikawa A; Tomioka A; Hori M; Nakato H; Kimura Y; Tokuda A; Takano A; Teramoto K; Murata S; Daigo Y
    PLoS One; 2024; 19(7):e0306995. PubMed ID: 39012903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
    Hibino M; Uryu K; Takeda T; Kunimatsu Y; Shiotsu S; Uchino J; Hirai S; Yamada T; Okada A; Hasegawa Y; Hiranuma O; Chihara Y; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T; Takayama K
    J Thorac Oncol; 2022 Aug; 17(8):1002-1013. PubMed ID: 35752437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Grima AA; Kwong JC; Richard L; Reid J; Raphael J; Basta NE; Carignan A; Top KA; Brousseau N; Blanchette PS; Sundaram ME;
    Vaccine; 2024 Mar; 42(7):1498-1505. PubMed ID: 38341288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.